
Aortitis triggered by granulocyte-colony stimulating factor

SHORT CASE REPORT

ANDREAS GAUSTAD

gaustada@gmail.com

Medical Department

Diakonhjemmet hospital

Oslo

Andreas Gaustad, specialty registrar in internal medicine and haematology

The author has completed the ICMJE form and declares no conflicts of interest.

MARTHE HALSAN LIFF

Rehabilitation Clinic

St. Olavs hospital, Trondheim University

Trondheim

Marthe Halsan Liff PhD, specialist in rheumatology, specialty registrar in physical medicine and rehabilitation

The author has completed the ICMJE form and declares no conflicts of interest.

ALEKSANDER NORDBERG NØRGAARD

Department of Radiology

Ullevål University Hospital

Oslo

Aleksander Nordberg Nørgaard, specialty registrar in radiology

The author has completed the ICMJE form and declares no conflicts of interest.

KRISTIN KIPLESUND FREMO

Department of Anaesthesiology

Ålesund hospital

Ålesund

Kristin Kiplesund Fremo, specialty registrar in anaesthesia

The author has completed the ICMJE form and declares no conflicts of interest.

Background

A man in his sixties was diagnosed with diffuse large B-cell lymphoma localised in the base of his tongue.

Case presentation

The patient was admitted to the emergency department with a fever, generalised muscle aches and lethargy 12 days after receiving his first chemotherapy treatment with granulocyte-colony stimulating factor (G-CSF) supplementation. There were no focal signs of infection. The patient was started on empiric antibiotic treatment. After four days, C-reactive protein (CRP) had increased from 104 to 331, but the patient's condition was largely unchanged. A computer tomography (CT) scan showed aortitis, most likely caused by G-CSF. The patient was treated with prednisolone and rapidly improved.

Interpretation

The diagnosis of G-CSF-induced aortitis should be considered in patients with fever after G-CSF treatment, particularly if adequate antibiotic treatment does not lead to improvement. Advanced imaging is often indicated. The most important measure is to discontinue G-CSF supplementation.

Aortitis triggered by granulocyte-colony stimulating factor (G-CSF) is a rare, but relevant differential diagnosis in patients with fever and elevated inflammatory markers receiving G-CSF-supported chemotherapy.

A man in his late sixties, who had undergone laparoscopic prostate surgery ten years earlier and had hypertension and atrial fibrillation, was diagnosed with diffuse large B-cell lymphoma localised in the base of his tongue. Lymphoma treatment was initiated with chemotherapy, consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP), as well as granulocyte-colony stimulating factor (G-CSF) with pegfilgrastim 6 mg subcutaneously on the third day of each chemotherapy cycle.

Twelve days after the first cycle, the man was admitted to hospital with fever, body aches and a diminished general condition that had lasted for two days. In the emergency department, his ear temperature was 38.5°C, blood pressure 132/75 mm Hg, pulse rate 85/min, respiratory rate 23/min and oxygen saturation 96 % in room air. C-reactive protein (CRP) was 104 mg/L (reference value: < 5), and neutrophil granulocytes were $12.6 \times 10^9/L$ (1.80–6.90). Evaluation showed no signs of focal

infection, and intravenous antibiotics consisting of phenoxymethylpenicillin 1.2 g $\times$ 4 and gentamicin 4 mg/kg $\times$ 1 were promptly initiated due to suspicion of infection with unknown focus.

Due to a lack of response to treatment after three days, the antibiotics were changed to intravenous cefotaxime 2 g $\times$ 3, combined with metronidazole 1.5 g $\times$ 1. On day four, the treatment was again switched to intravenous meropenem 1 g $\times$ 3 and vancomycin 1 g $\times$ 2. CRP had risen to 331, and the patient was still experiencing fever spikes $> 38.7^{\circ}\text{C}$. He was also now reporting mild chest pain but was considered to have unusually few signs of infection. All cultures were negative, a chest X-ray was normal, and transthoracic echocardiography showed no signs of endocarditis. On day four, a contrast-enhanced computed tomography (CT) scan of the chest, abdomen and pelvis was performed, leading to the correct diagnosis. The CT scan revealed vasculitic changes in the aorta and several branch vessels (Figure 1). G-CSF-induced aortitis was considered the likely diagnosis, and after an interdisciplinary discussion, peroral treatment with prednisolone 40 mg $\times$ 1 was initiated. Over the next few days, the patient became afebrile, and CRP decreased significantly. Antibiotics were discontinued after seven days, and the patient was discharged in good health after ten days. Prednisolone was tapered and discontinued over the course of three months. The lymphoma was successfully treated with four R-CHOP cycles, followed by two cycles of rituximab monotherapy. G-CSF was not administered again after the first cycle. Two years after initiating treatment, there were still no signs of lymphoma or vasculitis relapse.




Figure 1 Computed tomography (CT) in the portal venous phase showed uniform wall thickening in the aorta and proximal branch vessels (red arrows, the top red arrow points to the left subclavian artery). No calcification was observed in the wall, but there were reactive changes and some free fluid around the aorta (blue arrows). The CT image was consistent with large vessel vasculitis.

Discussion

Diffuse large B-cell lymphoma is a high-grade lymphoma that often responds well to chemotherapy. A common problem during treatment is neutropenic fever (1). G-CSF is given to reduce the risk of severe infections and thereby maintain high dose intensity, which is crucial for treatment outcome. G-CSF typically has few side effects. Large vessel vasculitis is a rare side effect, with an estimated incidence ranging from $\geq 1/10,000$ to $< 1/1000$ (2–6). Published case reports suggest that the condition is most common in women (3), although this can partly be explained by the high proportion of breast cancer and gynaecological cancers in the literature. Pegylated forms of G-CSF may have a stronger association with aortitis than non-pegylated formulations (7–8).

Vasculitis should be considered as a differential diagnosis in patients with fever and elevated inflammatory markers following G-CSF treatment, particularly if antibiotic therapy is ineffective. The median onset of symptoms is eight days after G-CSF treatment (3). Pain in the neck and chest regions can occur but is a nonspecific symptom. The exact pathogenesis is unknown, but it is established that G-CSF induces large-scale mobilisation of neutrophils (1, 9). One possible mechanism is therefore that the high number of circulating neutrophils and inflammatory cytokines from stimulated myeloid cells induce vasculitis. A high tumour burden has been suggested as a risk factor (3), but this was not observed in this case report.

Imaging is crucial for diagnostics and preventing unnecessary antibiotic treatment. Ultimately, the CT scan with contrast in the portovenous phase led us to the correct diagnosis. For targeted investigations or follow-up of extracranial vasculitis, positron emission tomography with integrated CT (PET/CT) or magnetic resonance imaging (MRI) are more suitable modalities (10). Malignancy and large vessel vasculitis sometimes occur simultaneously, but this is more often a coincidence than a paraneoplastic phenomenon. True paraneoplastic vasculitis typically affects small and medium-sized vessels and is more common in hematologic cancers than in other types of cancer (11). Paraneoplasia cannot be ruled out in our patient, but we believe that G-CSF was most likely the trigger. Other diagnostic tests showed no evidence of an underlying rheumatic condition. Prednisolone was tapered relatively quickly compared to, for example, treatment for temporal arteritis. The role of corticosteroids in treating this condition remains unclear, and further research is needed to determine the most effective approach. In a systematic review article from 2021, with 49 reported cases of G-CSF-induced aortitis, no significant difference was found in the time from onset to remission with or without corticosteroid treatment (3). Discontinuation of G-CSF is important for achieving remission from vasculitis.

The patient has consented to publication of the article.

The article has been peer-reviewed.

REFERENCES

1. Mhaskar R, Clark OA, Lyman G et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. *Cochrane Database Syst Rev* 2014; 2014: CD003039. [PubMed]
2. Asif R, Edwards G, Borley A et al. Granulocyte colony stimulating factor (G-CSF)-induced aortitis in a patient undergoing adjuvant chemotherapy for breast cancer. *BMJ Case Rep* 2022; 15. doi: 10.1136/bcr-2021-247237. [PubMed] [CrossRef]
3. Hoshina H, Takei H. Granulocyte-colony stimulating factor-associated aortitis in cancer: A systematic literature review. *Cancer Treat Res Commun* 2021; 29. doi: 10.1016/j.ctarc.2021.100454. [PubMed][CrossRef]
4. Taimen K, Heino S, Kohonen I et al. Granulocyte colony-stimulating factor- and chemotherapy-induced large-vessel vasculitis: six patient cases and a systematic literature review. *Rheumatol Adv Pract* 2020; 4. doi: 10.1093/rap/rkaa004. [PubMed] [CrossRef]
5. Nishimura M, Morita M, Okuyama Y et al. A Case of Aortitis Caused by Pegfilgrastim Use during Neoadjuvant Chemotherapy for Treating Breast Cancer. *Gan To Kagaku Ryoho* 2022; 49: 573–6. [PubMed]
6. Felleskatalogen. Ziextenzo. <https://www.felleskatalogen.no/medisin/ziextenzo-sandoz-659913?markering=0> Accessed 4.12.2024.
7. Lee SY, Kim EK, Kim JY et al. The incidence and clinical features of PEGylated filgrastim-induced acute aortitis in patients with breast cancer. *Sci Rep* 2020; 10: 18647. [PubMed][CrossRef]
8. Yukawa K, Mokuda S, Yoshida Y et al. Large-vessel vasculitis associated with PEGylated granulocyte-colony stimulating factor. *Neth J Med* 2019; 77: 224–6. [PubMed]
9. Theyab A, Algahtani M, Alsharif KF et al. New insight into the mechanism of granulocyte colony-stimulating factor (G-CSF) that induces the mobilization of neutrophils. *Hematology* 2021; 26: 628–36. [PubMed][CrossRef]
10. Dejaco C, Ramiro S, Bond M et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. *Ann Rheum Dis* 2024; 83: 741–51. [PubMed][CrossRef]
11. Lötscher F, Pop R, Seitz P et al. Spectrum of Large- and Medium-Vessel Vasculitis in Adults: Neoplastic, Infectious, Drug-Induced, Autoinflammatory, and Primary Immunodeficiency Diseases. *Curr Rheumatol Rep* 2022; 24: 293–309. [PubMed][CrossRef]

Publisert: 11. April 2025. Tidsskr Nor Lægeforen. DOI: 10.4045/tidsskr.24.0466
Received 4.9.2024, first revision submitted 19.12.2024, accepted 23.1.2025.

